| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Nov 19, 2020- Reduction in number of attacks is leading factor when evaluating prophylactic therapyKING OF PRUSSIA, Pa. 19 Nov 2020 CSL Behring, a global biotherapeutics leader, today announced survey results showing that a vast majority of HAE patients (94%) say it’s important their...
-
Nov 16, 2020- 6 Urban League Affiliates across U.S. to participate -- starting with Philadelphia
KING OF PRUSSIA, Pa. and PHILADELPHIA, Pa. 16 Nov 2020 Global biotherapeutics leader CSL Behring today announced a community partnership with six Urban League affiliates across the U.S., starting...
-
Nov 10, 2020Global biotherapeutics leader reinforces commitment to cardiovascular research: Hosts Learning Studio with prominent cardiovascular thought leaders to discuss emerging treatment targets
KING OF PRUSSIA, Pa. 10 Nov 2020 Global biotherapeutics leader CSL Behring today announced that results of two separate analyses will be shared at this year’s American Heart Association (AHA)...
-
Nov 5, 2020The AEGIS-II trial is evaluating the efficacy and safety of CSL112 (apolipoprotein A-1 [human]) during the high-risk 90-day period following a heart attack
KING OF PRUSSIA, Pa. 05 Nov 2020 Global biotherapeutics leader CSL Behring today announced that the study design manuscript for its landmark AEGIS-II (ApoA-I Event reducinG in Ischemic Syndromes...
-
Nov 2, 2020• Both US and European regulators grant special designation
KING OF PRUSSIA, Pa. 02 Nov 2020 Global biotherapeutics leader CSL Behring announced today that its investigational, plasma-derived hemopexin therapy (CSL889) received orphan drug designation from...